Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wuhan Wuyao Pharmaceutical is a leading Chinese pharmaceutical manufacturer and a core subsidiary of Grand Pharmaceutical Group. The company is globally recognized as a major producer of core Active Pharmaceutical Ingredients (APIs), particularly specializing in the epinephrine and norepinephrine series. Their extensive product portfolio covers therapeutic areas such as cardiovascular health, emergency medicine, and respiratory care. With large-scale GMP-certified manufacturing facilities, Wuhan Wuyao supplies high-quality chemical raw materials and finished preparations to both domestic and international markets. The company plays a critical role in the global supply chain for essential emergency medicines and maintains a strong focus on quality control and regulatory compliance.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Wuhan Wuyao.